臺灣韓國傳統醫藥法之比較

Comparison of Taiwan and Korea's Traditional Medicine Law

「韓國」2003年8月6號制定《韓醫藥育成法》，「中國」2016年12月25日通過《中醫藥法》，「臺灣」也終於在2019年12月31日制定《中醫藥發展法》。韓國《韓醫藥育成法》公佈到現在已經進行三次的五年綜合發展計劃「第1次韓醫藥育成發展計劃（2006年－2010年），「第2次韓醫藥育成發展計劃（2011年－2015年）」及目前還在進行中的「第3次韓醫藥育成發展計劃（2016年－2020年）」，目前韓國的傳統醫學（韓醫）比臺灣更多元化發展、法制面更健全、服務場域更成熟、國家的支援和產學的合作更緊密。在此簡單比較兩國傳統醫藥發展法的立法過程、比較及差異點，供臺灣後續制定相關施行辦法或子法的參考。台灣《中醫藥發展法》有24個條文，因為是「醫療法」的延伸還有部份是「藥事法」比較敏感的調劑問題等等，但其整體構成面比韓國《韓醫藥育成法》更廣，以基本法的精神制定，但是目前有缺遠程發展規劃及醫藥產學合作模式之開發等，還有很多繼續努力的項目。

“Korea” enacted the” Korean Medicine and Pharmaceutics Promotion Act” on August 6, 2003, “China” passed the “Chinese Medicine Law” on December 25, 2016, and “Taiwan” finally formulated the “Chinese Medicine and Pharmacy Development Act” on December 31, 2019. South Korea's “Korean Medicine and Pharmaceutics Promotion Act” has announced that it has carried out three-times five-year total development plan “the first Comprehensive Plan to Foster Korean Medicine and Pharmaceutics” (2006-2010), “the second Comprehensive Plan to Foster Korean Medicine and Pharmaceutics” (2011-2015) and “the third Korean Comprehensive Plan to Foster Korean Medicine and Pharmaceutics” (2016-2020) currently underway. At present, Korean traditional medicine (Korean medicine) is more diversified and more legal than Taiwan, non-insurance market is more mature, and national support and industry-university cooperation are closer. Here is a brief comparison of the legislative process and differences between the traditional medicine development laws of the two countries for reference of Taiwan's subsequent formulation of relevant implementation methods or sub-laws. Taiwan's “Chinese Medicine and Pharmacy Development Act. “ has 24 articles, because it is an extension of the “Medical Law” and part of it is the solution to the more sensitive adjustment problems of the “Pharmaceutical Law”, but it s overall composition is higher than that of the Korean Medicine and Pharmaceutics Promotion Act is broader and formulated in the spirit of the Basic Law. However, there are still many projects that continue to work hard, such as the lack of remote development planning and the development of the pharmaceutical industry-university cooperation model.